In 1980, it was discovered that B. pertussis could attach to hamstertrachealepithelial cells, and also, that the supernatant from the cultured bacterium could disrupt the cell cycle of uninfected cells. This prompted the scientists W. E. Goldman, D. G. Klapper, and J. B. Baseman to isolate and characterize a novel substance from B. pertussis supernatant. The noveldisaccharidetetrapeptide that they had purified showed toxicity for HTE cells and tracheal ring cultures. Subsequently, they named the newly sequestered molecule tracheal cytotoxin.
Structure
TCT is a soluble piece of peptidoglycan found in the cell wall of all gram-negative bacteria. Like all PGNs, TCT is composed of a disaccharide and a peptide chain. The IUPAC name for TCT is N-acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl--alanyl-γ--glutamyl-mesodiaminopimelyl--alanine. It is classified as a DAP-type PGN due to the third amino group within the chain being a diaminopimelyl peptide.The DAP residue is responsible for directly bonding to the D-alanine peptide of another PGN molecule, thus aiding TCT's attachment within the cell wall. The DAP portion of TCT also implies importance in cytopathogenicity as analogs lacking DAP show a significant reduction in toxicity.
Mechanism of Pathogenesis
Most Gram-negative bacteria keep TCT within the cell wall by using a PGN-transporter protein known as AmpG. However, B. pertussis is not capable of recycling PGNs via AmpG and thus, TCT escapes into the surrounding environment. Also, TCT appears to be constitutively expressed by B. pertussis. The first murine-model studies using TCT involved treatment of hamster tracheal cells. These experiments alluded to TCT's role in ciliostasis and cellular extrusion of ciliated hamster cells. Also, HTE cells had a markedly reduced level of DNA synthesis post-treatment with TCT. While previous studies using murine models reported evidence of TCT causing ciliostasis, in vitro studies using human tracheal cells have shown that TCT does not affect ciliary beat frequency of living cells, but instead causes damage and eventual extrusion of ciliated cells. In gonorrhea infections, vaginal ciliated epithelial cells have also displayed the same cytopathogenic effects due to TCT recognition. The extensive damage to ciliated epithilial tissue caused by TCT results in major disruption to the ciliary escalator; an important asset of the host's non-specific defenses. This disruption hinders the host's ability to remove mucous and foreign microbes from the epithelial tissue. Paroxysmal cough, e.g. whooping cough, is a direct symptom of said mucous build-up due to ciliated tissue damage. NOD-1 recognition and the presence of Lipooligosaccharide are two factors that modulate the effect of TCT. NOD-1 is a pattern recognition receptor that detects peptidoglycan. This receptor reacts weakly to TCT in humans, but robustly in mice. TCT is thought to work synergystically with LOS to mediate an inflammatory response, thus causing damage to ciliated epithelial cells. Notably, the human pathogens that produce excess TCT, causing damage to cilia also both produce LOS in their outer membrane.
TCT has been classified as an adjuvant molecule because of the stimulating effects it has on the immune system. Cellular damage associated with TCT is thought to be a result of increased levels of nitric oxide secretion by mucosal cells as part of an innate defense response to extracellular lipopolysaccharide and TCT. In humans, peptidoglycan recognition proteins, e.g. PGRPIαC, appear to bind with TCT and consequently induce the Tumor Necrosis Factor Receptor pathway. Studies using murine macrophages have shown that TCT encourages cytokine secretion, probably through the Nod1 receptor. As a pleiotropic toxin, TCT also acts as a pyrogen and as a stimulant of slow-wave sleep.
